Abstract. PTC gene, which is derived from the rearranged form of the ret proto-oncogene, was originally discovered in human thyroid papillary carcinomas. This gene has been thought to act as a tumorigenetic factor in thyroid carcinoma, although the action of PTC oncogene products is still unknown. To study the frequency of the PTC gene present in human thyroid carcinomas, we investigated four cell lines derived from thyroid carcinoma and 22 thyroid tumor tissue specimens. The reverse transcriptase-polymerase chain reaction (RT-PCR) method was performed to detect putative PTC mRNA. The presence of the PTC gene in genomic DNA was analyzed by Southern blot hybridization. PTC mRNA was detected by the RT-PCR method in only one papillary carcinoma cell line (TPC-1 cell). Southern gel analysis confirmed the rearrangement of the ret proto-oncogene in this cell line. In the other three cell lines and 22 tumor tissue specimens, however, neither the PTC gene or mRNA was detected. These results demonstrate that the prevalence of the PTC gene in thyroid tumor is low and may not be essential for human thyroid tumorigenesis. That our present results conflict with previous reports may be due to general differences in genetic background among races.
IT IS NOW widely accepted that human neoplasms arise as a result of a series of mutations affecting the structure of genes involved in growth control. It is generally considered that an accumulation of 5-6 different gene abnormalities is needed to initiate tumor formation in man [1] . Abnormalities in specific genes, the so-called proto-oncogenes or anti-oncogenes, were indeed found in certain neoplasms [2] . In human thyroid tumors, abnormalities in some proto-oncogenes have already been reported. Point mutations in the ras proto-oncogene in 20-25% of thyroid follicular adenomas and thyroid papillary carcinomas have been reported [3, 4] . Recently, the novel rearrangement of the ret proto-oncogene, which was named the PTC gene, was specifically found in thyroid papillary carcinomas [5, 6] 
IN HUMAN THYROID CARCINOMAS
The mixture amplification of the DNA fragment employed 30 cycles with 2.5U Tag polymerase (Perkin Elmer-Cetus Co., Norwalk, CT) and 1 mM oligonucleotide primers [9] . As illustrated in Fig.  2 , three separate amplification reactions were carried out for each sample in a total volume of 100 µl. The oligonucleotide primers used were; P-1: 5'-CATTGTCATCTCGCCGTTCC-3', P-2: 5'-GCGGTTCTCCTCCTGCAGTG-3', P-3: 5'-T-GGTTCTTGGAAAAACTCTA-3'
and P-4: 5,-C-CTGGCTGCAGGCCCCATAC-3'.
The PCR mixture contained 10 mM Tris (pH 8 
Results
The presence of the PTC gene in the tumor tissues was checked using by Southern gel analysis (Fig. 1) . Two restriction fragments (6.3 kb and 2.3 (20bp): P-1, P-2, 1'-3, P-4, P-1 -P-2 = 133bp, P-3--P-4 = 2I9bp, P-1 -1'-4 = kb) were hybridized with a [32P]-labelled ret probe after EcoRI digestion of normal thyroid tissue DNA (Fig. 1, lane 2) and thyroid tumor DNA (Fig .  1, lanes 3-8) , although smaller fragments were observed in lane 1. This result indicates that the rearrangement of the ret proto-oncogene exists in the TPC-1 cell line. Figure 2 shows the schema of the PTC cDNA. The rearrangement point of the PTC gene is present upstream of the tyrosine kinase domain of the ret cDNA. Four different oligonucleotide primers (P-1, P-2, P-3 , P-4), two of them located on the H4 cDNA region and the other two on the tyrosine kinase domain of ret cDNA, were synthesized. If the PTC gene exists and is expressed, the cDNA fragment between P-1 and P-4 should be amplified. In one papillary carcinoma cell line, TPC-1 cell line, the PTC cDNA fragment was detected (Fig . 3, lane 3) . To confirm that the amplified DNA was the PTC cDNA fragment, the amplified product was digested with a restriction enzyme , EcoRI or BamHI, since these restriction sites in the PTC cDNA should produce fragments 178 bp , 235 by and 165 bp, 248 by in size, respectively, the 413 by fragment amplified with P-1 and P-4 was cut with EcoRl or BamHI into appropriate sizes (Fig . 3 , lanes E and Ba). The amplified DNA of H4 cDNA (P-1 -P-2) and ret cDNA (P-3 -P-4), which were of and P-2, Lane B: DNAs were amplified using P-1 and P-4. putative size 133 bp (lane 1) and 219 bp (lane 2), respectively, were also recognized on the 10% acrylamide gel by ethidium bromide staining. This means that this cell line has the PTC gene. On the other hand, amplified DNA 413 bp in size was not observed in the thyroid tumor DNA when oligonucleotide primers P-1 and P-4 were used (lane B) as shown in Fig. 4 , although the amplified DNA was clearly recognized by using oligonucleotide primers P-1 and P-2 (lane A; 133 bp). These results indicate that the H4 gene was expressed but the PTC gene was not expressed in the other cell lines and tissues we checked. Table 1 
Discussion
The PTC gene, which was first described in thyroid papillary carcinoma, is a rearrangement gene derived from the recombination of the ret proto-oncogene with the 5'-terminal sequence, 354 bp long, called H4 [10] . As these two genes are located on the same chromosome 10q, intrachromosomal recombination in tumor cells might have formed the PTC gene [11] . It has already been found that several types of rearrangement forms of ret proto-oncogene exist. The ret protooncogene was first isolated from a human T-cell lymphoma [12] . Like several other transforming genes, the ret proto-oncogene encodes a protein structurally related to transmembrane receptors with a cytoplasmic tyrosine kinase domain [13] . Takahashi et al. reported one rearrangement form which was activated by the fusion of a sequence encoding tyrosine-kinase domain of the ret protooncogene to the 5'-terminal portion of a gene encoding a putative zinc-finger domain [14] . Subsequently, two different rearrangements of the ret oncogene have been reported, the first one from a human sigmoid colon cancer (ret II) [15] and the second one from a human gastric cancer [16] . These three rearrangement forms, which led to the activation of the ret oncogene [16] , occurred in vitro during the transfection assay. Grieco et al. reported that the PTC gene existed and was expressed in 5 of 20 thyroid papillary carcinoma tissues and they considered it might affect tumorigenesis in thyroid papillary carcinomas [6] . In this study, however, the PTC gene was detected in only one papillary carcinoma cell line (TPC-1 cell) which presents aberrant transcripts of ret protooncogene [17] . We could not detect the PTC gene in 22 tumor tissues including 10 thyroid papillary carcinoma tissues. 
